Wolverine Trading
RIGL icon

Wolverine Trading’s Rigel Pharmaceuticals RIGL Stock Holding History

Wolverine Trading’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,276
Closed -$13.4K – 5098
2024
Q1 		$18.9K Buy
+1,276
New +$17.2K ﹤0.01% 4339
2021
Q2 		– Sell
-1,788
Closed -$67.5K – 6571
2021
Q1 		$61K Buy
+1,788
New +$70.8K ﹤0.01% 5609
2020
Q4 		– Sell
-1,421
Closed -$41.1K – 5367
2020
Q3 		$33K Buy
+1,421
New +$34.9K ﹤0.01% 4335
2019
Q1 		– Sell
-3,518
Closed -$79K – 5169
2018
Q4 		$79K Buy
3,518
+1,232
+54% +$34.8K ﹤0.01% 4057
2018
Q3 		$73K Buy
2,286
+700
+44% +$21K ﹤0.01% 4628
2018
Q2 		$56K Hold
1,586
– – ﹤0.01% 4883
2018
Q1 		$56K Sell
1,586
-1,481
-48% -$59.3K ﹤0.01% 4883
2017
Q4 		$119K Buy
+3,067
New +$117K ﹤0.01% 4401
2016
Q4 		– Sell
-3,490
Closed -$125K – 5005
2016
Q3 		$125K Sell
3,490
-1,417
-29% -$40.6K ﹤0.01% 4093
2016
Q2 		$106K Buy
+4,907
New +$122K ﹤0.01% 3603

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's RIGL Position: Q2 2024 in Review

Wolverine Trading sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 1,276 shares — an estimated $13.4K sold.

Wolverine Trading first reported a position in RIGL in Q2 2016 and held it in 10 quarters. The position peaked at $125K in Q3 2016. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Wolverine Trading reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 1,276 Rigel Pharmaceuticals shares in Q2 2024, an estimated $13.4K.
  • Wolverine Trading first reported a position in Rigel Pharmaceuticals in Q2 2016 and held it in 10 quarters.
  • Wolverine Trading's Rigel Pharmaceuticals position peaked at $125K in Q3 2016.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.